Core Viewpoint - The company *ST Changyao is focusing on becoming a leading platform in the health industry, primarily engaged in the production and sales of traditional Chinese medicine, medicinal capsules, and the wholesale of pharmaceuticals, health products, and medical devices [1][10]. Group 1: Company Overview - *ST Changyao is classified under the pharmaceutical and biological sector, specifically in traditional Chinese medicine [2][10]. - The company aims to build an integrated pharmaceutical industry chain that includes the production of traditional Chinese medicine, hollow capsules, and a medical logistics network [1]. Group 2: Financial Misconduct - On November 7, 2025, the company received a notice from the China Securities Regulatory Commission regarding suspected false reporting of financial data [2][10]. - The company reported inflated revenues for 2021, 2022, and 2023, amounting to 215.32 million, 283.74 million, and 233.63 million yuan respectively, which represented 9.12%, 17.57%, and 19.51% of the disclosed revenues for those years [5][12]. - The inflated total profits for the same years were reported as 56.40 million, 63.38 million, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the disclosed total profits [5][12]. Group 3: Investor Compensation - Investors who purchased shares between April 28, 2022, and November 7, 2025, and sold or continued to hold them after November 8, 2025, are eligible for compensation [5][12]. - Additionally, investors who bought shares between March 30, 2019, and April 29, 2024, and sold or continued to hold them after April 30, 2024, can also participate in the compensation [9][15]. Group 4: Financial Issues and Risks - As of April 30, 2024, the company disclosed significant financial issues, including a fund occupation amounting to 179.66 million yuan, which is 92.08% of the latest audited net assets [6][14]. - The company has acknowledged internal control deficiencies regarding non-operational fund occupation by its former general manager and related parties from 2019 to 2023 [7][14].

Market Overview - During the week of November 10 to November 14, the A-share market saw a collective decline in the three major indices, with the Shanghai Composite Index closing at 3990.49 points, down 0.18% for the week, the Shenzhen Component Index at 13216.03 points, down 1.40%, and the ChiNext Index at 3111.51 points, down 3.01% [2] - Over 56% of individual stocks experienced gains during the week, with 170 stocks rising over 15% and 23 stocks declining over 15%. Sectors such as textiles, retail, beauty care, biomedicine, and food and beverage saw increases, while communication, electronics, computers, machinery, and defense industries faced declines [2] Top Performing Stocks - Huasheng Lithium Battery (688353.SH) led the weekly gainers with a remarkable 79.61% increase, followed by Haike Xinyuan (301292.SZ) at 71.38%. Other notable gainers included Jindike (688670.SH), Furui Shares (002083.SZ), Renmin Tongtai (600829.SH), and Dongbai Group (600693.SH), all exceeding 61% in weekly gains [4] - The stock price of Huasheng Lithium Battery reached a historical high, closing at 139.20 yuan, with a total market capitalization of 22.2 billion yuan. The stock has seen a cumulative increase of over 172% from November 5 to November 14 [5][6] Huasheng Lithium Battery Details - Huasheng Lithium Battery specializes in the research, production, and sales of lithium battery electrolyte additives, with a significant market presence in China and exports to Japan, South Korea, the United States, Europe, and Southeast Asia. The company ranked first in domestic market share for lithium-ion battery electrolyte additives from 2018 to 2020 [5] - The recent price surge in the electrolyte industry has driven the prices of additive products higher, with battery-grade vinyl carbonate rising from 48,800 yuan/ton to 57,000 yuan/ton in October, and a significant daily increase of 8.13% to 66,500 yuan/ton on November 10 [5][6] Underperforming Stocks - *ST Changyao (300391.SZ) was the worst performer of the week, with a decline of 33.62%. Other stocks such as Haitan Shares (603759.SH), Degute (300950.SZ), and Bangji Technology (603151.SH) also saw declines exceeding 17% [9] - The company is under investigation by the China Securities Regulatory Commission for suspected financial fraud, which may lead to forced delisting if significant violations are confirmed [10][11] *ST Changyao Company Overview - *ST Changyao operates in the pharmaceutical industry, focusing on the production and sales of traditional Chinese medicine pieces, medicinal capsules, and medical logistics. The company has faced challenges, including a warning of potential delisting due to negative net profits over the past three years [10][11] - The company reported a revenue of 105 million yuan for the first three quarters of 2025, a year-on-year increase of 4.4%, but a net loss of 210 million yuan, a decline of 15.89% [12]